NEWS RELEASE

Teijin Pharma Launches YORVIPATH®, a First of its Kind Treatment in Japan for the Rare Disease Hypoparathyroidism

Tokyo, November 6, 2025 — Teijin Pharma Limited, the core company of the Teijin Group's Teijin healthcare business, announced today the launch of YORVIPATH® (palopegteriparatide), a first of its kind treatment in Japan for adults with the rare endocrine disease hypoparathyroidism. This novel parathyroid hormone (PTH) replacement therapy is self-administered once daily by pen device to maintain PTH levels within the physiological range for 24 hours/day. The launch follows Teijin Pharma's acquisition of a development and commercialization license for YORVIPATH® in Japan from Ascendis Pharma A/S, a global biopharmaceutical company headquartered in Copenhagen, Denmark.

Hypoparathyroidism is an endocrine disease caused by insufficient levels of PTH, the primary regulator of calcium and phosphate levels in the body. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications. These include characteristic muscle spasms in the arms and legs known as tetany, as well as numbness in the limbs and around the mouth. In severe cases, the condition may affect the entire body and cause epilepsy-like seizures. In the long term, there is a risk of developing complications, including renal impairment, ectopic calcification and cognitive dysfunction.

Current conventional therapy for hypoparathyroidism consists of active vitamin D and calcium, which aim to address hypocalcemia. However, despite use of conventional therapy, individuals may experience fluctuations in serum calcium levels, symptoms, and poor quality of life. This therapy may also cause hypercalcemia, hypercalciuria, nephrocalcinosis, nephrolithiasis and renal dysfunction. There is a need for a new treatment that can maintain physiological PTH levels for 24 hours per day.

YORVIPATH® is a prodrug of PTH (1-34) developed by Ascendis Pharma, based on its TransCon technology, designed to provide active PTH within the physiological range for

24 hours/day in adults with hypoparathyroidism. It is administered once daily by subcutaneous injection using a pre-filled pen. This drug is expected to be a fundamental treatment for hypoparathyroidism in Japan.

YORVIPATH® has been designated as an orphan drug in Japan, the United States and Europe. Ascendis Pharma has received regulatory approval for YORVIPATH® for the treatment of adults with hypoparathyroidism in the United States, the European Union, Norway, Iceland, Liechtenstein and Great Britain (covering England, Wales and Scotland and Australia). It has also been made available to patients in other countries under named patient programs.

Based on the data from a Phase III clinical trial conducted by Ascendis Pharma in Japan, Teijin Pharma received manufacturing and marketing approval for YORVIPATH® from the Ministry of Health, Labour and Welfare in August 2025. The drug was listed in the National Health Insurance price list in October 2025 and launched on November 6, 2025.

By combining its business foundation in home healthcare with pharmaceuticals and medical devices, Teijin Pharma seeks to allow patients to receive treatment comfortably at home.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people. Teijin is committed to its Purpose, "Pioneering solutions together for a healthy planet." Teijin works together with employees and external partners to achieve its Long-Term Vision, "To be a company that supports the society of the future." Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.
Visit www.teijin.com

Press Contact
Corporate Communication Department
Teijin Limited
+81 (0)3 3506 4055
pr@teijin.co.jp